Metastatic Prostate Cancer Interventions added to androgen-deprivation therapy in men with
metastatic prostate cancer have recently been noted to increase survival. Decisions about …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Purpose Germline mutations in DNA damage repair (DDR) genes are identified in a
significant proportion of patients with metastatic prostate cancer, but the clinical implications …

Importance Prostate cancer is the third leading cause of cancer-related death in men in the
United States. Although serious, most of these diagnoses are not terminal. Inherited risk for …

Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer
(mCRPC), but there have been few whole-genome sequencing (WGS) studies of this …

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …

Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …